Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Investig Allergol Clin Immunol ; 18(5): 335-42, 2008.
Article in English | MEDLINE | ID: mdl-18973096

ABSTRACT

Recombinant protein technology and the subsequent development of biologic agents for pharmacotherapy have greatly improved the treatment of a wide variety of diseases in humans. These products are subject to reactions not previously seen in other drug classes. Additionally, subtle alteration in the manufacture or administration of a biologic agent may cause reactions in subjects who previously tolerated it. This review highlights the unique immunologic reactions that are associated with the more commonly used biologic agents.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Biological Therapy/adverse effects , Drug Hypersensitivity/etiology , Immunity , Insulin/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Animals , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Antigens, CD/immunology , Biological Therapy/methods , Cloning, Molecular , Drug Hypersensitivity/prevention & control , ErbB Receptors/immunology , Humans , Insulin/genetics , Insulin/immunology , Receptor, ErbB-2/immunology , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Tumor Necrosis Factor-alpha/immunology
SELECTION OF CITATIONS
SEARCH DETAIL